Based on research at Drexel University, Context Therapeutics is seeking to raise up to $21m in an initial public offering on Nasdaq.
Context Therapeutics, a US-based developer of treatments for cancers affecting women based on research at Drexel University, has filed for an initial public offering that could raise up to $21m.
The company will issue 1.5 million shares and has set a price range of $12 to $14. It aims to list on Nasdaq Capital Market using the ticker symbol CNTX.
Founded in 2015, Context Therapeutics is working on advanced small molecule and immunotherapy treatments for hormone-driven breast…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
